Pharmaceutical Preparations · DE · CIK 1528115
Annexon develops novel therapies blocking C1q and the classical complement pathway for autoimmune and neurodegenerative diseases
Comparable business profile · signals at a glance
In the 90 days to Mar 10, 2026: 1 insider bought $66K · 5 sold $313K.
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| Mar 10, 2026 | Carson William H.Director | Buy | 8,000 | $5.67 | $45K |
| Mar 2, 2026 | Artis Dean RichardEVP & CHIEF SCIENTIFIC OFFICER | Sell | 5,894 | $5.43 | $32K |
| Mar 2, 2026 | Dananberg JamieCHIEF MEDICAL OFFICER | Sell | 5,820 | $5.43 | $32K |
| Mar 2, 2026 | Yednock TedEVP & CHIEF INNOVATION OFFICER | Sell | 5,566 | $5.42 | $30K |
| Mar 2, 2026 | Lew JenniferEVP & CHIEF FINANCIAL OFFICER | Sell | 5,565 | $5.42 | $30K |
| Mar 2, 2026 | Overdorf MichaelEVP & CHIEF BUSINESS OFFICER | Sell | 4,339 | $5.42 | $24K |
| Feb 18, 2026 | Yednock TedEVP & CHIEF INNOVATION OFFICER | Sell | 7,857 | $5.11 | $40K |
| Feb 18, 2026 | Lew JenniferEVP & CHIEF FINANCIAL OFFICER | Sell | 7,851 | $5.11 | $40K |
| Feb 18, 2026 | Overdorf MichaelEVP & CHIEF BUSINESS OFFICER | Sell | 6,225 | $5.10 | $32K |
| Feb 18, 2026 | Dananberg JamieCHIEF MEDICAL OFFICER | Sell | 5,290 | $5.10 | $27K |
| Feb 18, 2026 | Artis Dean RichardEVP & CHIEF SCIENTIFIC OFFICER | Sell | 5,290 | $5.10 | $27K |
| Dec 30, 2025 | Carson William H.Director | Buy | 4,115 | $5.02 | $21K |
| Dec 1, 2025 | Choi JungDirector | Buy | 33,000 | $4.19 | $138K |
| Dec 1, 2025 | Carson William H.Director | Buy | 4,115 | $4.47 | $18K |
| Nov 21, 2025 | Satter Muneer ADirector | Buy | 422,613 | $4.28 | $1.8M |
| Nov 20, 2025 | Satter Muneer ADirector | Buy | 400,000 | $4.48 | $1.8M |
| Nov 19, 2025 | Satter Muneer ADirector | Buy | 500,000 | $3.94 | $2.0M |
| Nov 18, 2025 | Satter Muneer ADirector | Buy | 500,000 | $3.18 | $1.6M |
| Nov 17, 2025 | Satter Muneer ADirector | Buy | 500,000 | $2.99 | $1.5M |
| Oct 30, 2025 | Carson William H.Director | Buy | 4,115 | $3.17 | $13K |
Open-market buys & sells (Form 4, transaction codes P/S). Source: SEC structured insider data.